Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
NCT00054470
First received: February 5, 2003
Last updated: June 27, 2012
Last verified: June 2012
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: January 2003
  Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)